Population pharmacokinetics of arbekacin in patients infected with methicillin-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 11, 2006, Pages 3754-3762

  Tanigawara, Yusuke ^a,d   Sato, Reiko ^a   Morita, Kunihiko ^a   Kaku, Mitsuo ^b   Aikawa, Naoki ^a   Shimizu, Kihachiro ^c  

^a KEIO UNIVERSITY HOSPITAL   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KITASATO INSTITUTE   (Japan)

^d KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; FOSFOMYCIN; HABEKACIN; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; COMPARTMENT MODEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONLINEAR SYSTEM; PATIENT CARE; PNEUMONIA; POPULATION RESEARCH; PRIORITY JOURNAL; SCHOOL CHILD; SEPSIS; STAPHYLOCOCCUS INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CHILD; DIBEKACIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; METHICILLIN RESISTANCE; MIDDLE AGED; MODELS, STATISTICAL; POPULATION; REPRODUCIBILITY OF RESULTS; SEPSIS; STAPHYLOCOCCAL INFECTIONS;

EID: 33750589806     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00420-05     Document Type: Article

References (47)

1. Aoki, Y. 1994. Bactericidal activity of arbekacin against methicillin-resistant Staphylococcus aureus. Comparison with that of vancomycin. Jpn. J. Antibiot. 47:640-646.
2. Arakawa, S., H. Maeda, A. Fujii, S. Kamidono, K. Hamada, S. Miyazaki, and S. Hara. 1989. Clinical study of aminoglycoside on renal dysfunction. Pharmacokinetics of arbekacin and its elimination effects by hemodialysis and adsorption with charcoal. Acta Urol. Jpn. 35:697-704.
3. Cockcroft, D. W, and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
4. de Hoog, M., R. C. Schoemaker, J. W. Mouton, and J. N. van den Anker. 1997. Tobramycin population pharmacokinetics in neonates. Clin. Pharmacol. Ther. 62:392-399.
5. Ette, E. I. 1997. Stability and performance of a population pharmacokinetic model. J. Clin. Pharmacol. 37:486-495.
6. Fillastre, J. P., A. Leroy, G. Humbert, B. Moulin, P. Bernadel, and S. Josse. 1987. Pharmacokinetics of habekacin in patients with renal insufficiency. Antimicrob. Agents Chemother. 31:575-577.
7. Fujimura, S., Y. Tokue, H. Takahashi, T. Nukiwa, K. Hisamichi, T. Mikami, and A. Watanabe. 1998. A newly recognized acetylated metabolite of arbekacin in arbekacin-resistant strains of methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 41:495-497.
8. Garrelts, J. C., G. Jost, S. F. Kowalsky, G. J. Krol, and J. T. Lettieri. 1996. Ciprofloxacin pharmacokinetics in burn patients. Antimicrob. Agents Chemother. 40:1153-1156.
9. Goodman, E. L., J. Van Gelder, R. Holmes, A. R. Hull, and J. P. Sanford. 1975. Prospective comparative study of variable dosage and variable frequency regimens for administration of gentamicin. Antimicrob. Agents Chemother. 8:434-438.
10. Hamilton-Miller, J. M. T., and S. Shah. 1995. Activity of the semi-synthetic kanamycin B derivative, arbekacin against methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 35:865-868.
11. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673.
12. Kashuba, A. D. M., A. N. Nafziger, G. L. Drusano, and J. S. Bertino, Jr. 1999. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob. Agents Chemother. 43:623-629.
13. Kimura, T., K. Sunakawa, N. Matsuura, H. Kubo, S. Shimada, and K. Yago. 2004. Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. Antimicrob. Agents Chemother. 48:1159-1167.
14. Kirkpatrick, C. M. J., S. B. Duffull, E. J. Begg, and C. Frampton. 2003. The use of a change in gentamicin clearance as an early predictor of gentamicin-induced nephrotoxicity. Ther. Drug Monit. 25:623-630.
15. Komiya, I., N. Mitomi, and M. Nishio. 1986. Assay method of HBK in biological fluids. II. High-performance liquid chromatographic assay method. Chemotherapy 34:82-86.
16. Kondo, S., K. Iinuma, H. Yamamoto, K. Maeda, and H. Umezawa. 1973. Syntheses of 1-N-{(S)-4-amino-2-hydroxybutyryl}-kanarnycin B and -3′, 4′-dideoxykanamycin B active against kanamycin-resistant bacteria. J. Antibiot. 26:412-415.
17. Kumon, H., A. Mizuno, Y. Nasu, M. Tsugawa, M. Kishi, and H. Ohmori. 1989. Pharmacokinetics of arbekacin in healthy volunteers and patients with renal insufficiency. Jpn. J. Antibiot. 42:200-207.
18. Lesne-Hulin, A., P. Bourget, F. Ravat, C. Goudin, and J. Latarjet. 1999. Clinical pharmacokinetics of ciprofloxacin in patients with major burns. Eur. J. Clin. Pharmacol. 55:515-519.
19. Lingvall, M., D. Reitb, and R. Broadbent 2005. The effect of sepsis upon gentamicin pharmacokinetics in neonates. Br. J. Clin. Pharmacol. 59:54-61.
20. Longley, J. M., D. G. Pittman, and F. D. Newby. 1991. Altered aminoglycoside volume of distribution in patients with acquired immunodeficiency syndrome. Clin. Pharm. 10:784-786.
21. Marik, P. E. 1993. Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth. Intensive Care 21:172-173.
22. Matsuhashi, Y., and H. Yamamoto. 1988. The enzymatic mechanisms of resistance to aminoglycoside antibiotics in methicillin-cephem-resistant Staphylococeus aureus. Jpn. J. Antibiot. 41:523-529.
23. Matsuno, T., N. Suzuki, S. Kawai, S. Han, Y. Mizutani, H. Fujii, and M. Takabashi. 1999. A method of effective administration for arbekacin (ABK)-2. Jpn. J. Ther. Drug Monit. 15:309-313.
24. Matsuo, H., J. Hayashi, K. Ono, K. Andoh, Y. Andoh, Y. Sano, K. Saruki, J. Tanaka, M. Yamashita, K. Nakamura, and K. Kubo. 1997. Administration of aminoglycosides to hemodialysis patients immediately before dialysis: a new dosing modality. Antimicrob. Agents Chemother. 41:2597-2601.
25. Mitomi, N., T. Matsumoto, M. Fujigaki, I. Komiya, and F. Kai. 1987. Absorption, distribution, and excretion of arbekacin after intravenous and intramuscular administration in rats. Jpn. J. Antibiot. 40:357-364.
26. Moore, R. D., P. S. Lietman, and C. R. Smith. 1987. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 155:93-99.
27. Moore, R. D., C. R. Smith, and P. S. Lietman. 1984. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am. J. Med. 77:657-662.
28. Nicolau, D. P., C. D. Freeman, P. P. Belliveau, C. H. Nightingale, J. W. Ross, and R. Quintiliani. 1995. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob. Agents Chemother. 39:650-655.
29. Oparaoji, E. C., E. E. Cornwell III, E. Hekmat, R. Lun Cheong, J. S. Adir, and S. Siram. 1993. Aminoglycoside volume of distribution in postoperative patients with septic shock. Clin. Pharm. 12:131-134.
30. Parke, J., N. H. G. Holford, and B. G. Charles. 1999. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput. Methods Programs Biomed. 59:19-29.
31. Ristuccia, A. M., and B. A. Cunha. 1985. An overview of amikacin. Ther. Drug Monit. 7:12-25.
32. Romano, S., M. M. Fdez de Gatta, M. V. Cairo, D. Caballero, A. Dominguez-Gil, and J. M. Lanao. 1999. Population pharmacokinetics of amikacin in patients with haematological malignancies. J. Antimicrob. Chemother. 44:235-242.
33. Rosario, M. C., A. H. Thomson, D. I. Jodrell, C. A. Sharp, and H. L. Elliott 1998. Population pharmacokinetics of gentamicin in patients with cancer. Br. J. Clin. Pharmacol. 46:229-236.
34. Rybak, M. J., B. J. Abate, S. Lena Rang, M. J. Ruffing, S. A. Lerner, and G. L. Drusano. 1999. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob. Agents Chemother. 43:1549-1555.
35. Sato, R., Y. Tanigawara, M. Kaku, N. Aikawa, and K. Sbimizu. 2006. Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococeus aureus. Antimicrob. Agents Chemother. 50:3763-3769.
36. Shibasaki, S., N. Mitomi, T. Matsumoto, N. Morishita, T. Matsuno, H. Fujii, Y. Tanigawara, and K. Okumura. 2000. Population pharmacokinetic analysis of arbekacin in Japanese. Jpn. J. Ther. Drug Monit. 17:47-53.
37. Shinkai, S., N. Ishiwatari, and M. Fujita. 1986. Assay method gf HBK in biological fluids. I. Microbiological assay method. Chemotherapy 34:72-81.
38. Sieradzki, K., P. Villari, and A. Tomasz. 1998. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci. Antimicrob. Agents Chemother. 42:100-107.
39. Suzuki, K., K. Tanikawa, and T. Matsuzaki. 2003. Pharmacokinetics and dosing of arbekacin in preterm and term newborn infants. Pediatr. Int. 45:175-179.
40. Tang, G. J., J. J. Tang, B. S. Lin, C. W. Kong, and T. Y. Lee. 1999. Factors affecting gentamicin pharmacokinetics in septic patients. Acta Anaesthesiol. Scand. 43:726-730.
41. Tominaga, T., H. Kishi, T. Nigima, T. Kawamura, M. Oshi, H. Nitoh, and I. Saitoh. 1988. A study on the pharmacokinetics of HBK in patients with renal impairment. Nishinihon J. Urol. 50:129-134.
42. Totsuka, K., K. Shimizu, N. Mitomi, T. Niizato, and M. Araake. 1994. Evaluation of once-daily administration of arbekacin. Experimental study and determination of pharmacokinetic properties in man. Jpn. J. Antibiot. 47:676-692.
43. Triginer, C., I. Izquierdo, R. Fernandez, J. Rello, J. Torrent, S. Benito, and A. Net 1990. Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med. 16:303-306.
44. Watanabe, T., K. Ohashi, K. Matsui, and T. Kubota. 1997. Comparative studies of the bactericidal, morphological and antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 39:471-476.
45. Yamamoto, Y., M. Koyama, and K. Nakagawa. 1986. Phase-one clinical study on HBK. Chemotherapy 34:104-116.
46. Yasuhara, M., T. Iga, H. Zenda, K. Okumura, T. Oguma, Y. Yano, and R. Hori. 1998. Population pharmacokinetics of vancomycin in Japanese adult patients. Ther. Drug Monit. 20:139-148.
47. Zaske, D. E., R. J. Cipolle, J. C. Rotschafer, L. D. Solem, N. R. Mosier, and R. G. Strate. 1982. Gentamicin pharmacokinetics in 1,640 patients: method for control of serum concentrations. Antimicrob. Agents Chemother. 21:407-411.